66 related articles for article (PubMed ID: 10554678)
21. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response.
Lee KA; Cho KJ; Kim SH; Shim JH; Lim JS; Cho DH; Song MS; Dinarello CA; Yoon DY
Cancer Lett; 2005 Nov; 229(2):261-70. PubMed ID: 16125299
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of vascular endothelial growth factor-C by nicotine in cervical cancer cell lines.
Lane D; Gray EA; Mathur RS; Mathur SP
Am J Reprod Immunol; 2005 Mar; 53(3):153-8. PubMed ID: 15727570
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins.
Bequet-Romero M; López-Ocejo O
Biochem Biophys Res Commun; 2000 Oct; 277(1):55-61. PubMed ID: 11027639
[TBL] [Abstract][Full Text] [Related]
24. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development.
Routes JM; Ryan S; Li H; Steinke J; Cook JL
Virology; 2000 Nov; 277(1):48-57. PubMed ID: 11062035
[TBL] [Abstract][Full Text] [Related]
25. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
26. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL
Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118
[TBL] [Abstract][Full Text] [Related]
27. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
28. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
29. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
30. The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism.
Clere N; Bermont L; Fauconnet S; Lascombe I; Saunier M; Vettoretti L; Plissonnier ML; Mougin C
Exp Cell Res; 2007 Sep; 313(15):3239-50. PubMed ID: 17678892
[TBL] [Abstract][Full Text] [Related]
31. [Effects of green tea extract on expression of human papillomavirus type 16 oncoproteins-induced hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human cervical carcinoma cells].
Tang XD; Zhou X; Zhang QZ; Le AD; Zhou KY
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(40):2872-7. PubMed ID: 19080502
[TBL] [Abstract][Full Text] [Related]
32. Adenoviral p53 effects and cell-specific E7 protein-protein interactions of human cervical cancer cells.
Choi JW; Ahn WS; Bae SM; Lee DB; Kim YW
Biosens Bioelectron; 2005 May; 20(11):2236-43. PubMed ID: 15797321
[TBL] [Abstract][Full Text] [Related]
33. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.
Jiang M; Milner J
Oncogene; 2002 Sep; 21(39):6041-8. PubMed ID: 12203116
[TBL] [Abstract][Full Text] [Related]
34. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
Lee DW; Anderson ME; Wu S; Lee JH
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
[TBL] [Abstract][Full Text] [Related]
35. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
36. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of jaceosidin isolated from Artemisiaargyi on the function of E6 and E7 oncoproteins of HPV 16.
Lee HG; Yu KA; Oh WK; Baeg TW; Oh HC; Ahn JS; Jang WC; Kim JW; Lim JS; Choe YK; Yoon DY
J Ethnopharmacol; 2005 Apr; 98(3):339-43. PubMed ID: 15814270
[TBL] [Abstract][Full Text] [Related]
38. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
[TBL] [Abstract][Full Text] [Related]
39. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
40. HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs).
Braun K; Ehemann V; Waldeck W; Pipkorn R; Corban-Wilhelm H; Jenne J; Gissmann L; Debus J
Cancer Lett; 2004 Jun; 209(1):37-49. PubMed ID: 15145519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
